
STERIS plc
HealthcareNYSE:STE · New York Stock Exchange
+$0.34 today
Vol 0.49M · Avg 0.77M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$5.9B of revenue converted into $782.4M of net income for the selected period. Gross margin is 44.3% and net margin is 13.2%, showing how much revenue survives after costs and taxes. EPS is $7.93, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.9B +8.7% | $5.5B +6.2% | $5.1B +13.3% | $4.5B +7.4% | $4.2B | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $3.3B +8.3% | $3.1B +4.7% | $2.9B +14.3% | $2.6B +9.2% | $2.3B | $344.8M | $725.6M | $804.0M |
| Gross Profit | $2.6B +9.3% | $2.4B +8.3% | $2.2B +12.0% | $2.0B +5.2% | $1.9B | $10.3B | $8.9B | $7.6B |
| Gross Margin | 44.2% +0.2pp | 44.0% +0.8pp | 43.2% -0.5pp | 43.7% -0.9pp | 44.6% | 45.5% | 9.8% | 28.9% |
| Research & Development | $112.9M +4.9% | $107.6M +3.8% | $103.7M +5.3% | $98.5M +13.6% | $86.7M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $1.4B +5.5% | $1.3B +6.5% | $1.3B +14.8% | $1.1B -17.3% | $1.3B | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $1.5B -0.7% | $1.5B +11.1% | $1.4B +16.2% | $1.2B -15.3% | $1.4B | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $0 -100.0% | $476.2M -15.8% | $565.2M +2.2% | $552.9M -0.0% | $553.1M | $1.2B | $374.2M | $1.2B |
| EBITDA | $1.1B -18.5% | $1.4B -3.8% | $1.4B +5.1% | $1.3B +33.1% | $1.0B | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | 18.7% -6.2pp | 24.9% -2.6pp | 27.5% -2.1pp | 29.6% +5.7pp | 23.9% | 10.0% | 5.6% | 46.3% |
| Operating Income | $1.1B +27.1% | $866.6M +3.7% | $836.1M +5.7% | $791.1M +65.6% | $477.8M | $10.6B | $12.3B | $14.0B |
| Operating Margin | 18.6% +2.7pp | 15.9% -0.4pp | 16.3% -1.2pp | 17.4% +6.1pp | 11.3% | 18.7% | 16.6% | 24.1% |
| Interest Income | $0 -100.0% | $8.4M -23.9% | $11.0M | $0 -100.0% | $6.3M | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $60.7M -29.6% | $86.3M -40.2% | $144.4M +30.2% | $110.8M +23.9% | $89.5M | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | -$54.5M +22.6% | -$70.4M +47.2% | -$133.3M -20.3% | -$110.8M +0.2% | -$111.0M | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | $1.0B +31.5% | $796.2M +13.3% | $702.8M +3.3% | $680.3M +85.5% | $366.8M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | 17.6% +3.1pp | 14.6% +0.9pp | 13.7% -1.3pp | 15.0% +6.3pp | 8.7% | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | $262.2M +42.0% | $184.7M +23.5% | $149.5M +20.5% | $124.1M +50.7% | $82.3M | $666.8M | $1.3B | -$1.6B |
| Net Income | $785.1M +27.7% | $614.6M +62.5% | $378.2M +253.4% | $107.0M -56.1% | $243.9M | $5.0B | $4.9B | $4.8B |
| Net Margin | 13.2% +2.0pp | 11.3% +3.9pp | 7.4% +5.0pp | 2.4% -3.4pp | 5.8% | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | $8 +27.1% | $6 +62.9% | $4 +257.9% | $1 -57.2% | $3 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | $8 +27.9% | $6 +62.7% | $4 +256.1% | $1 -56.9% | $2 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $98.2M -0.4% | $98.6M -0.2% | $98.8M -0.9% | $99.7M +2.2% | $97.5M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $98.7M -0.4% | $99.1M -0.3% | $99.4M -0.9% | $100.2M +2.0% | $98.3M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector

Biogen Inc.
NASDAQ:BIIB
$29.53B

DexCom, Inc.
NASDAQ:DXCM
$29.08B

Koninklijke Philips N.V.
NYSE:PHG
$25.70B

West Pharmaceutical Services, Inc.
NYSE:WST
$23.23B

Waters Corporation
NYSE:WAT
$23.17B

Quest Diagnostics Incorporated
NYSE:DGX
$22.48B

Labcorp Holdings Inc.
NYSE:LH
$21.83B

Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.13B

Smith & Nephew plc
NYSE:SNN
$12.97B

Insulet Corporation
NASDAQ:PODD
$10.37B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does STE generate?
STERIS plc (STE) reported $5.94B of revenue in fiscal 2026.
Is STE profitable?
STERIS plc (STE) reported $785.10M of net income, with a net margin of 13.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.